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Disseminated Mycobacterium kansasii infection is a rare infection in non-HIV patients. This
research has uncovered a very rare manifestation of disseminated M. kansasii infection in a
non-HIV patient with lung and pericardial involvement.
 2012 Published by Elsevier Ltd. on behalf of Asian-African Society for Mycobacteriology.Case presentation
The main responsible organisms for non-tuberculosis
mycobacteria (NTM) infections in HIV positive patients are
Mycobacterium Avium Complex (MAC) and Mycobacterium
kansasii [1]. These infections, although rare, can be fatal
[2,3]. This research has uncovered a rare infection associated
withM. kansasii in a non-HIV patient with several noteworthy
aspects. In January 2005, a 37-year-old male was admitted to
the hospital with complaints of cough and fever of two
months’ duration. Four months prior to his admittance to
the hospital, the patient was hospitalized in another center
presenting with pancytopenia and diagnosed with
Myelodysplastic Syndrome (MDS) of refractory anemia with
excess blast type after aspiration and bone marrow biopsy.
The patient was then treated with Cyclosporine and Danazol.
Two months later the patient developed fever, dry cough, and
weight loss, and 20 days prior to his admittance at this center,
the patient suffered from progressive cough and dyspnea. The
patient had no history of smoking, opium use, or high-risk
sexual behavior. Upon physical examination, the patientshed by Elsevier Ltd. on b
arsi).looked ill and appeared toxic (BP = 110/70, P = 90, RR = 24,
T = 39 C). Other than bilateral wheezes and reduced sounds
over the left lung, there were no other significant abnormali-
ties upon physical examination. The chest X-ray revealed a
mass in the upper lobe of the left lung (see Fig. 1). A Spiral
CT Scan demonstrated a mass in the left upper lobe (LUL)
along with infiltration around the area, consolidation in LUL
and lingual, along with mediastinal lymphadenopathy, a left
pleural effusion, and pericardial effusion. In the primary anal-
ysis of respiratory specimens, the smear was found positive
for Acid-Fast Bacillus (AFB) and the standardized treatment
regimen for tuberculosis was started. In addition, predniso-
lone (50 mg/daily) was prescribed because of TB pericarditis.
On the 15th day of hospitalization, the patient had an episode
of dyspnea associated with a drop in blood pressure, and
underwent surgery for a pericardial window and biopsy of
the pericardium. The smear of the pericardial fluid was
negative for AFB. Diagnostic bronchoscopy showed vegetative
tissue in the LLL opening accompanied by mucosal irregular-
ity. A smear from the BAL was positive for AFB. A poorly-
formed histiocytic granuloma with many AFB was reportedehalf of Asian-African Society for Mycobacteriology.
Fig. 1 – Patient X-ray revealed a mass in the upper lobe left
lung; diagnosis as Mycobacterium kansasii.
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pericardial biopsy only showed chronic fibrosis. On the 20th
day of hospitalization, the patient’s general state had
improved and he was afebrile. On follow-up, the culture of
bronchoalveolar lavage (BAL) and pericardium were both
positive for mycobacteria. On the basis of Bergey’s Manual
of Systematic Bacteriology, conventional biochemical tests
(obtained from the Department of Mycobacteriology, National
Institute of Public and the Environment, The Netherlands)
were consistent with M. kansasii [4,5]. At this point, all of
the previous anti-tuberculosis medications were continued
except for Pyrazinamide (PZA). After 18 months of treatment,
the chest X-ray appears completely normal, sputum culture is
AFB negative, and the patient is currently on the list for bone
marrow transplantation. Until the HIV/AIDS epidemic, infec-
tions related to M. kansasii were rarely reported [1,2]. Lilo
and colleagues reported eight cases related to M. kansasii in
which all patients had systemic problems, six of whom were
on steroids [6].
The presented case contains 3 major points
• The condition first appeared as a lung tumor;
• The condition showed vegetative tissue (endobronchial
lesion) in the bronchoscopy;
• Pericardial involvement.
The clinical manifestations of patients with NTM are asso-
ciated with fever and chills and in many cases these manifes-
tations are very similar to tuberculosis [7]. In patients with
defective immune systems, the infections associated with
NTM should be taken into consideration. Pericardial compli-
cations with M. kansasii are very rare, and all such cases have
been reported in HIV-positive patients [8]. At the time of
writing this report, this case is the first such report with
M. kansasii in an HIV-negative patient. The other interestingobservation was the presence of endobronchial complica-
tions. This presentation has been reported in less than ten
patients, all of them were HIV-positive patients [9].
Treatment of M. kansasii in immunocompetent patients is
usually successful. However, in patients with defective im-
mune systems, this infection is accompanied by high mortal-
ity rates. Even though standardized anti-TB treatment is
useful for M. kansasii, recognition of this infection is impor-
tant because longer drug regimens (18 months) are necessary.
In addition, because of the lack of PZA efficacy in M. kansasii,
the elimination of this from the drug regimen helps in the
reduction of side effects [10].
In conclusion, a patient withM. kansasii infection that pre-
sented with pericardial complications, endobronchial vegeta-
tive lesions, and appearance mimicking a tumor has been
reported. With the improvement in diagnostic methods, the
determination of the NTM infections should be considered
in individuals with depressed immune systems that present
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